
Global Cord Blood Corporation CO
Annual report 2022
added 08-16-2022
Global Cord Blood Corporation General and Administrative Expenses 2011-2025 | CO
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Global Cord Blood Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 187 M | 174 M | 190 M | 424 M | 483 M | 380 M | 326 M | 265 M | 231 M | 205 M | 161 M | 139 M |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 483 M | 139 M | 264 M |
Quarterly General and Administrative Expenses Global Cord Blood Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 44.5 M | - | - | - | 42.7 M | - | - | - | 49.4 M | - | - | - | 40 M | - | - | - | 52.8 M | - | - | - | 48.3 M | - | - | - | 42.6 M | - | - | - | 31 M | - | - | - | 28 M | 27.4 M | - | - | 29 M | 25.1 M | 23.1 M | 22.7 M | 21.4 M | 22.5 M | 23.3 M |
All numbers in CNY currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 52.8 M | 21.4 M | 33.8 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Brainsway Ltd.
BWAY
|
5.78 M | $ 19.06 | -1.6 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 20.31 | -5.8 % | $ 221 M | ||
|
Co-Diagnostics
CODX
|
14.3 M | $ 0.23 | -4.17 % | $ 6.75 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Castle Biosciences
CSTL
|
200 M | $ 39.2 | -0.49 % | $ 1.09 B | ||
|
Danaher Corporation
DHR
|
7.76 B | $ 230.87 | 0.23 % | $ 169 B | ||
|
DarioHealth Corp.
DRIO
|
18.1 M | $ 10.36 | 3.19 % | $ 294 M | ||
|
BioNano Genomics
BNGO
|
51.9 M | $ 1.51 | -0.9 % | $ 1.92 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
Exact Sciences Corporation
EXAS
|
191 M | $ 101.86 | 0.28 % | $ 18.9 B | ||
|
DexCom
DXCM
|
1.19 B | $ 67.65 | 0.12 % | $ 26.1 B | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 26.63 | -0.34 % | $ 805 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
118 M | $ 19.19 | -1.49 % | $ 1.03 B | ||
|
Celcuity
CELC
|
9.06 M | $ 101.0 | -1.22 % | $ 3.98 B | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
Anixa Biosciences
ANIX
|
7.44 M | $ 3.19 | -0.31 % | $ 102 K | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
IQVIA Holdings
IQV
|
1.99 B | $ 227.26 | 0.15 % | $ 41.2 B | ||
|
Guardant Health
GH
|
180 M | $ 100.93 | -1.99 % | $ 12.4 B | ||
|
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | ||
|
Myriad Genetics
MYGN
|
276 M | $ 6.32 | -2.55 % | $ 573 M | ||
|
ENDRA Life Sciences
NDRA
|
7.06 M | $ 4.75 | -4.81 % | $ 2.55 M | ||
|
Neogen Corporation
NEOG
|
218 M | $ 7.2 | 0.98 % | $ 1.56 B | ||
|
National Research Corporation
NRC
|
46.6 M | $ 18.95 | 1.55 % | $ 465 M | ||
|
Illumina
ILMN
|
1.09 B | $ 134.56 | -0.29 % | $ 21.4 B | ||
|
Charles River Laboratories International
CRL
|
751 M | $ 203.33 | -0.11 % | $ 10.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.77 B | $ 175.36 | -0.34 % | $ 19.5 B | ||
|
Biodesix
BDSX
|
80.5 M | $ 6.79 | -0.44 % | $ 880 M | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
Koninklijke Philips N.V.
PHG
|
599 M | $ 27.26 | 0.57 % | $ 20 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.23 B | $ 252.95 | -0.4 % | $ 21.2 B | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 182.75 | -0.05 % | $ 15.1 B | ||
|
IDEXX Laboratories
IDXX
|
442 M | $ 685.99 | -0.36 % | $ 56.6 B | ||
|
Lantheus Holdings
LNTH
|
194 M | $ 67.0 | 0.43 % | $ 4.64 B | ||
|
Personalis
PSNL
|
46.2 M | $ 8.01 | -1.6 % | $ 475 M | ||
|
Mettler-Toledo International
MTD
|
936 M | $ 1 419.41 | -0.06 % | $ 30.1 B | ||
|
Agilent Technologies
A
|
1.62 B | $ 138.09 | -0.22 % | $ 42 B | ||
|
Quidel Corporation
QDEL
|
66.6 M | $ 29.27 | -0.12 % | $ 1.23 B | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.6 | -3.7 % | $ 5.97 M |